Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Peringkat dalam Saham #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Harga Saham
$0.0568
Terakhir disinkronkan: 2026-08-13
Kapitalisasi Pasar
$661.36K
Perubahan (1 hari)
11.37%
Perubahan (1 tahun)
-5.33%
Negara
US
Perdagangan Hepion Pharmaceuticals, Inc. (HEPA)

Kategori

EPS untuk Hepion Pharmaceuticals, Inc. (HEPA)
EPS per 2026 TTM: 0
Menurut laporan keuangan terbaru dan harga saham Hepion Pharmaceuticals, Inc., EPS perusahaan saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki EPS sebesar 0 sama dengan EPS tahun 2026 sebesar 0.
Riwayat EPS untuk Hepion Pharmaceuticals, Inc. dari 2026 hingga 2026
EPS di akhir setiap tahun
Tahun EPS Mengubah
Tidak cukup data untuk tanggal yang disediakan.
EPS untuk perusahaan sejenis atau pesaing
Perusahaan EPS Perbedaan EPS Negara
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE